RE:RE:Big pharmas are watching us closely! Imagine the upfront $$$ to access to our technology.
If we're to become a future SOC, our Ph. 2 data will be valued extremely high, when you see a perspective like below, as our first successful indication would di facto confirm the huge potential of our ACT platform.
GSK has responded by inking a deal to buy privately held Affinivax for $2.1 billion upfront and two $600 million milestones tied to pediatric clinical development. The takeover will give GSK full control of a 24-valent pneumococcal vaccine candidate that Affinivax plans to move into phase 3 in older adults and phase 1/2 trials in children this year. The Merck and Pfizer vaccines that won approval last year protect against 15 and 20 strains of pneumococcal serotypes, respectively.